Advertisement


Nicholas C. Turner, MD, PhD, on New Data on Capivasertib and Fulvestrant for Advanced Breast Cancer

2022 San Antonio Breast Cancer Symposium

Advertisement

Nicholas C. Turner, MD, PhD, of London’s Institute of Cancer Research and The Royal Marsden, discusses phase III results from the CAPItello-291 clinical trial, which showed that in patients with hormone receptor–positive, HER2-negative tumors resistant to aromatase inhibitors, adding the investigational AKT inhibitor capivasertib to fulvestrant doubled the median progression-free survival compared with placebo plus fulvestrant (Abstract GS3-04).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
AKT inhibition is common in advanced hormone receptor positive HER2 negative breast cancers. The CAPitello 291 study investigated the AKT inhibitor, capivasertib. The study recruited patients with advanced hormone receptor positive HER2 negative breast cancer that had progressed on prior aromatase inhibitor. The study allowed up to two prior lines of endocrine therapy and one prior line of chemotherapy for advanced breast cancer, and also allowed prior CDK4/6 inhibitor, mandating 51% of patients to have had a prior CDK4/6 inhibitor at least. 708 patients were recruited, randomized one to one between fulvestrant and placebo and fulvestrant and capivasertib. There were two co-primary endpoints. Investigator assessed PPFs overall and in AKT pathway activated cancers. AKT pathway activated cancers were defined as the presence of PIC3CA, AKT1, or P10 mutations in the cancer, which was determined in tissue, which was submitted after randomization and analyzed with the FoundationOne assay. Overall, 41% of tumors had AKT pathway activating alterations. Overall, median PFS improved from 3.6 months on fulvestrant and placebo to 7.2 months on capivasertib and fulvestrant. A hazard ratio of 0.6, highly statistically significant. Then in the co-primary endpoint of AKT pathway activated cancers, PFS improved from 3.1 months on placebo to 7.2 months on capivasertib. A hazard ratio of 0.5. Again, highly statistically significant. If we come to adverse effects, overall capivasertib was well tolerated with a manageable safety profile. 13% of patients stopped due to adverse effects. The most prominent adverse effect was diarrhea, which occurred in 72% of patients, predominantly grade one diarrhea, although 9% of patients had grade three diarrhea. Rash also occurred in 38% of patients, 12% grade three, but prominently both hypoglycemia and stomatitis were relatively uncommon, grade three and only 2% of patients each. Overall the CAPitello 291 study showed a statistically significant and clinically meaningful improvement in progression-free survival, both overall and in AKT pathway activated cancers. The benefit was consistent across subgroups including in patients with prior CDK46 inhibitor use. Currently, overall survival data is immature and ongoing follow-up is going on for two further formal analyses of overall survival. In conclusion, it is hopeful that capivasertib will be a future treatment option for the population of patients who were recruited in the study.

Related Videos

Breast Cancer

Ann H. Partridge, MD, MPH, on Interrupting Breast Cancer Treatment to Attempt Pregnancy

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the POSITIVE trial, which showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy, does not affect short-term disease outcomes. The study found that 74% of women had at least one pregnancy, most (70%) within 2 years. Birth defects were low (2%) and were not clearly associated with treatment exposure. Dr. Partridge explains that these data stress the need to incorporate patient-centered reproductive health care in the treatment and follow-up of young women with breast cancer (Abstract GS4-09).

Breast Cancer

Andrea De Censi, MD, on Noninvasive Breast Cancer: 10-Year Results on Low-Dose Tamoxifen

Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, discusses phase III findings showing that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Babytam at 5 mg/d for 3 years significantly lowered recurrence from noninvasive breast cancer at 10 years without “excess” adverse events (Abstract GS4-08).

 

Breast Cancer

Erica L. Mayer, MD, PhD, on Metastatic Breast Cancer: New Findings on Palbociclib After Prior CDK4/6 Inhibitor and Endocrine Therapy

Erica L. Mayer, MD, PhD, of Dana-Farber Cancer Institute, discusses findings from the PACE study of patients with endocrine- and CDK4/6 inhibitor–pretreated estrogen receptor–positive/HER2-negative metastatic breast cancer who were randomly assigned to fulvestrant alone; fulvestrant and palbociclib; or fulvestrant, palbociclib, and avelumab. Combining palbociclib with fulvestrant beyond disease progression on a prior CDK4/6 inhibitor regimen did not improve progression-free survival compared with fulvestrant alone. A longer progression-free survival when a PD-L1 inhibitor was added to fulvestrant and palbociclib deserves further study. A baseline circulating tumor DNA analysis suggests that the potential benefit of palbociclib after progression on a prior CDK4/6 inhibitor may be influenced by ESR1 or PIK3CA status (Abstract GS3-06).

Breast Cancer

Sean Khozin, MD, MPH, on Randomized Trials vs Real-World Evidence in Patients With Advanced Cancer

Sean Khozin, MD, MPH, of the Massachusetts Institute of Technology, discusses the “external validity deficits” of randomized clinical trials, which still involve only about 5% of adults with cancer, who may differ in important ways from real-world populations. Dr. Khozin describes the reasons for low levels of participation and advocates for capturing the experience of patients not represented in traditional clinical trials, so real-world data can address these validity deficits.

Breast Cancer

Joseph A. Sparano, MD, on Long-Term Breast Cancer Recurrence and Survival Data from TAILORx

Joseph A. Sparano, MD, of the Tisch Cancer Center at Mount Sinai Health System, discusses long-term clinical outcomes data that continue to show many women with early breast cancer can safely forgo chemotherapy, when guided by the 21-gene recurrence score result. The longer follow-up also showed that recurrences of breast cancer continue to occur years after the original diagnosis, although these recurrences were not prevented by chemotherapy use. Racial disparities were not explained by inequities in social determinants of health or treatment adherence, with Black women at higher risk of early recurrence within the first 5 years of diagnosis, but not later recurrence after 5 years (Abstract GS1-05).

Advertisement

Advertisement




Advertisement